Stock Market Reviews

LYEL (Lyell Immunopharma, Inc.) News

Get the latest news, insights, and market updates on LYEL (Lyell Immunopharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs
  Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.
  Feb 13, 2026 - $LYEL
• Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
  PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line settingThe pivotal single-arm trial, PiNACLE, evaluating ronde-cel in the third- or later-line setting is ongoing with BLA submission expected in 2027Site activation for both PiNACLE – H2H and PiNACLE are underway in the United States, Canada and Aust
  Feb 12, 2026 - $LYEL
• The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
  Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
  Dec 26, 2025 - $LYEL
• 4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
  MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
  Dec 24, 2025 - $LYEL
• Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain
  Key Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable...
  Dec 17, 2025 - $LYEL
• Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
  93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell managem
  Dec 7, 2025 - $LYEL
• Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
  Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.
  Nov 12, 2025 - $LYEL
• Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
  Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trialReceived RMAT designation from the U.S. FDA for ronde-cel for the treatment of patients with relapsed or refractory LBCL receiving treatment in the second-
  Nov 12, 2025 - $LYEL
• Lyell Immunopharma: Q3 Earnings Snapshot
  SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Wednesday reported a loss of $38.8 million in its third quarter.
  Nov 12, 2025 - $LYEL
• Lyell acquires worldwide rights from ICT to CAR T-cell therapy
  US Phase I clinical trial data reveal dose-dependent activity of LYL273 in 12 patients.
  Nov 11, 2025 - $LYEL